- Home
- REBN vs SNGX Comparison
REBN vs SNGX Comparison
Compare REBN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- SNGX
- Stock Information
- Founded
- REBN 2015
- SNGX 1987
- Country
- REBN United States
- SNGX United States
- Employees
- REBN N/A
- SNGX N/A
- Industry
- REBN Restaurants
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- SNGX Health Care
- Exchange
- REBN Nasdaq
- SNGX Nasdaq
- Market Cap
- REBN 8.6M
- SNGX 7.4M
- IPO Year
- REBN 2022
- SNGX 1987
- Fundamental
- Price
- REBN $4.49
- SNGX $2.31
- Analyst Decision
- REBN
- SNGX
- Analyst Count
- REBN 0
- SNGX 0
- Target Price
- REBN N/A
- SNGX N/A
- AVG Volume (30 Days)
- REBN 6.5M
- SNGX 623.6K
- Earning Date
- REBN 03-27-2025
- SNGX 03-14-2025
- Dividend Yield
- REBN N/A
- SNGX N/A
- EPS Growth
- REBN N/A
- SNGX N/A
- EPS
- REBN N/A
- SNGX N/A
- Revenue
- REBN $5,502,528.00
- SNGX $364,183.00
- Revenue This Year
- REBN $185.18
- SNGX N/A
- Revenue Next Year
- REBN $64.55
- SNGX $76.64
- P/E Ratio
- REBN N/A
- SNGX N/A
- Revenue Growth
- REBN 9.70
- SNGX N/A
- 52 Week Low
- REBN $0.92
- SNGX $1.83
- 52 Week High
- REBN $8.80
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- REBN 86.57
- SNGX 34.85
- Support Level
- REBN $1.39
- SNGX $2.33
- Resistance Level
- REBN $2.76
- SNGX $2.63
- Average True Range (ATR)
- REBN 0.64
- SNGX 0.25
- MACD
- REBN 0.30
- SNGX -0.01
- Stochastic Oscillator
- REBN 70.09
- SNGX 17.73
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an innovative company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).